- Company name
- Vertex Pharmaceuticals
- Sector
- Biotechnology
- About
- Vertex Pharmaceuticals makes medicines for serious diseases. Its main business is cystic fibrosis (CF): its CFTR modulators, such as TRIKAFTA/KAFTRIO and ALYFTREK, can treat about 95% of people with CF in its core markets. It also sells CASGEVY, a gene-edited therapy for sickle cell disease and beta thalassemia, JOURNAVX, a non-opioid medicine for acute pain, and PALSONIFY for acromegaly, which it got when it bought Crinetics Pharmaceuticals in September 2026. In Q3 2026, revenue was $3.44 billion, and CF medicines gave $3.27 billion of it. Its pipeline includes povetacicept for kidney diseases, inaxaplin for APOL1-mediated kidney disease, suzetrigine for nerve pain and cell therapies for type 1 diabetes. It trades on the Nasdaq.
- Thesis
- Vertex trades at a premium because investors pay for its near-monopoly in CF and for new businesses that can grow after CF. CF revenue grew 7.7% in Q3 2026, and the patients take the medicines for life, and ALYFTREK extends the franchise. Investors also expect new products in kidney disease, pain, endocrine disease and diabetes. For the premium to be earned, four things must be true. The FDA must approve povetacicept for IgA nephropathy by the target date of November 30, 2026, and the launch must grow fast in 2027. JOURNAVX, CASGEVY and PALSONIFY must keep growing; in Q3 2026, JOURNAVX revenue nearly tripled and CASGEVY revenue was nearly six times that of a year earlier. The Phase 3 studies of suzetrigine in diabetic nerve pain must succeed in mid-2027, and the inaxaplin interim analysis in early 2027 must support accelerated approval. CF revenue must keep growing while patients move to ALYFTREK. The premium can shrink if a key study fails, if povetacicept is late, or if US drug price rules lower CF prices. The approval decision on November 30, 2026 and the 2027 guidance in the Q4 2026 report, expected in early 2027, are the next tests.
- Risks
- CF medicines give about 95% of revenue. Lower prices from US drug price rules or from payers in Europe, or a new rival medicine, can cut profit.
Much of the value depends on new medicines. The FDA can delay or refuse povetacicept, and the suzetrigine nerve pain studies or the inaxaplin study can fail.
Vertex paid about $10.0 billion for Crinetics. If PALSONIFY and atumelnant sell less than planned, the purchase can lower returns, and the costs lower earnings per share in 2026 and 2027.
Launches of CASGEVY and JOURNAVX need time. Cell therapy centers and pain prescribers adopt new medicines slowly, so revenue can grow more slowly than investors expect.
Vertex now has $4.5 billion of term loan debt at floating rates. Higher interest rates raise its costs.
- Balance sheet
- Cash: $9.8B
Debt: $4.5B
Net cash: $5.3B
Undrawn credit line: $500M, to July 2031
Debt due within 12 months: $1.0B
Last debt due: 2029
Vertex had cash, cash equivalents and marketable securities of $9.8 billion at September 30, 2026, down from $12.3 billion at December 31, 2025. The decrease came mainly from $9.0 billion of net cash for Crinetics Pharmaceuticals and buybacks. Debt is a $4.5 billion term loan at SOFR plus a margin, borrowed on September 1, 2026. It is due in three parts: $1.0 billion on August 31, 2027, $1.0 billion on September 1, 2028 and $2.5 billion on August 31, 2029. The loan can be prepaid without penalty. A $500 million revolving credit facility runs to July 30, 2031 and is undrawn. Operating cash flow was $3.197 billion in the first nine months of 2026, and capital spending was $342.9 million. Vertex bought back 2.0 million shares for $921.3 million in that time, and $2.5 billion of buyback authorization was left at September 30, 2026.
As of 2026-09-30.
- Checkpoints
- Nov 30, 2026: FDA decision on povetacicept in IgA nephropathy. Pending. Watch: Accelerated approval by the target date passes; a delay or a refusal fails.
Feb 2, 2027 (estimate): Q4 2026 results and 2027 guidance. Pending. Watch: 2027 revenue guidance with growth near 10% or more and a fast povetacicept start pass; flat CF revenue or weak launch figures fail.
Q2 2027 (estimate): Inaxaplin interim analysis and suzetrigine nerve pain results. Pending. Watch: Data that support accelerated approval of inaxaplin and positive Phase 3 results for suzetrigine in diabetic nerve pain in mid-2027 pass; a failed study fails.
- Recent events
- 2026-11-02: Vertex reported Q3 2026 results. Revenue rose 12% to $3.44 billion. CF revenue was $3.27 billion, ALYFTREK revenue was $705.8 million, CASGEVY revenue was $99 million and JOURNAVX revenue was $58 million. Non-GAAP EPS was $4.76, against $4.80 a year earlier, because of Crinetics costs and lower interest income. GAAP net income fell to $654 million because of about $500 million of acquisition costs. Vertex raised its 2026 revenue guidance to $13.15 billion to $13.25 billion.
2026-10-20: Vertex added Daniel Brennan, a former Chief Financial Officer of Boston Scientific, to its board.
2026-09-01: Vertex completed its purchase of Crinetics Pharmaceuticals for an equity value of about $10.0 billion, or $9.0 billion net of the cash it got. It borrowed $4.5 billion under a new term loan for the purchase.
2026-08-27: Vertex named Jonathan Poole, its Senior Vice President of Finance, as Chief Financial Officer from January 1, 2027. Charles Wagner stays Chief Operating Officer.
2026-08-03: Vertex reported Q2 2026 results. Revenue rose 12% to $3.33 billion, and Vertex raised its 2026 revenue guidance to $13.1 billion to $13.2 billion.
2026-07-06: Vertex agreed to buy Crinetics Pharmaceuticals, which makes PALSONIFY for acromegaly and develops atumelnant for congenital adrenal hyperplasia.
2026-03-31: Vertex completed its application to the FDA for accelerated approval of povetacicept in IgA nephropathy. It used a priority review voucher, and the FDA later set a target date of November 30, 2026.